Compare Shopify Inc. (SHOP) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Shopify Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? Shopify Inc. trades at $170.85 (market cap $211.73B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: Shopify Inc. is far larger — about 20.9× State Street SPDR S&P Biotech ETF's market cap, and Shopify Inc. is trading nearer its 52-week high, State Street SPDR S&P Biotech ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Shopify Inc. for 78 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| SHOP | XBI | |
|---|---|---|
Market Cap | $211.73B | $10.11B |
Volume | 7,146,651 | 12,903,266 |
Sector | Technology | Broad Market / Factor |
52-Week High | $179.01 | $169.55 |
52-Week Low | $95.40 | $104.99 |
Typical Hold Time | 78 Days | 38 Days |
Enterprise Value | $206.96B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Shopify (SHOP) trades at $164.54, down 0.84% on the day, with strong technical momentum showing bullish moving average signals despite overbought RSI readings. The company demonstrates robust revenue growth, with 2025 revenue reaching $11.56 billion and net income of $1.23 billion, though valuation metrics remain elevated with a P/E of 111. Recent developments include the launch of Canvas AI store-building tools and expanding payment services.
Shopify maintains strong growth trajectory with accelerating merchant solutions revenue and expanding AI capabilities. However, premium valuation multiples and competitive pressures from Amazon pose risks. Analyst consensus remains bullish with 67% buy ratings and $168.63 price target, suggesting modest upside potential from current levels.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Shopify Inc.
Shopify Inc. provides a cloud-based commerce platform. The Company offers a platform for merchants to create an omni-channel experience that helps showcase the merchant's brand.
Read more on SHOP →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
